Arrowhead Pharmaceuticals...

NASDAQ: ARWR · Real-Time Price · USD
20.29
1.51 (8.04%)
At close: Aug 15, 2025, 3:44 PM

Arrowhead Pharmaceuticals Income Statement

Financials in USD. Fiscal year is October - September.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Sep 30, 2024 Sep 30, 2023 Sep 30, 2022 Sep 30, 2021
Revenue
3.55M 240.74M 243.23M 138.29M
Cost of Revenue
18.59M 12.49M 10.42M n/a
Gross Profit
3.55M 240.74M 243.23M 138.29M
Operating Income
-601.08M -205M -178.51M -149.04M
Interest Income
22.72M 15.3M 5.03M 6.12M
Pretax Income
-612.46M -206.49M -172.71M -140.85M
Net Income
-599.49M -205.28M -176.06M -140.85M
Selling & General & Admin
96.82M 90.93M 124.43M 80.98M
Research & Development
505.87M 353.19M 297.31M 206.34M
Other Expenses
1.94M 1.62M n/a n/a
Operating Expenses
604.63M 445.74M 421.74M 287.32M
Interest Expense
32.35M 18.33M n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
604.63M 445.74M 421.74M 287.32M
Income Tax Expense
-2.77M 2.78M 3.79M 2K
Shares Outstanding (Basic)
119.78M 107.31M 105.43M 103.75M
Shares Outstanding (Diluted)
119.78M 106.75M 105.43M 103.75M
EPS (Basic)
-5 -1.91 -1.67 -1.36
EPS (Diluted)
-5 -1.92 -1.67 -1.36
EBITDA
-561.51M -175.67M -162.29M -132.58M
EBIT
-580.11M -188.16M -172.71M -140.85M
Depreciation & Amortization
18.59M 12.49M 10.42M 8.27M